JPMorgan analyst Jessica Fye lowered the firm’s price target on BioNTech to $90 from $99 and keeps an Underweight rating on the shares. The analyst updated the company’s model to reflect the Q4 earnings results and 2024 guidance. The firm believes downward revisions to long-term estimates and protracted time lines to meaningful pipeline readouts could hinder the stock’s ability to recover.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX: